Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 8/20 | 0.48 |
| ▸ | TTR | P02766 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.31 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129366 | 0.86 | TNK2 (0.41) | TNK2BTK | |
| SCHEMBL1129239 | 0.85 | TNK2 (0.56) | TNK2BTK | |
| SCHEMBL4360608 | 0.84 | TNK2 (0.47) | TNK2IGF1R | |
| SCHEMBL398951 | 0.82 | TNK2 (0.34) | TNK2 | |
| SCHEMBL1129132 | 0.79 | TNK2 (0.41) | TNK2BTK | |
| SCHEMBL2458195 | 0.79 | IGF1R (0.47) | TNK2IGF1R | |
| SCHEMBL1128792 | 0.79 | TNK2 (0.43) | TNK2BTK | |
| SCHEMBL1129007 | 0.79 | TNK2 (0.43) | TNK2BTK | |
| SCHEMBL1129227 | 0.79 | TNK2 (0.41) | TNK2 | |
| SCHEMBL398095 | 0.77 | IGF1R (0.34) | IGF1RFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | claimed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | claimed |
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | TNK2 2837/4885TTR 575/4885BTK 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.